latest news releases from the newsroom
Kirin International Holding, Inc.
Kirin International Submits Application to Trade on NASDAQ
NEW YORK, July 30, 2015 (GLOBE NEWSWIRE) -- Kirin International Holdings Inc. (OTCBB:KIRI) (the "Company"), a non-state-owned real estate development company focused on residential and commercial real estate development in "tier-three" cities in the People's Republic of China, today announced the Company has submitted an initial listing application to the NASDAQ Stock Market to have its common stock approved for listing on the NASDAQ Capital Market. The NASDAQ Stock Market is an American stock exchange which is the second-largest exchange in the world by market capitalization.
ChemoCentryx Announces Changes to its Board of Directors
MOUNTAIN VIEW, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that effective July 28, 2015, Thomas A. Edwards, retired partner of Latham & Watkins, LLP, has been appointed to the Company's Board of Directors. Mr. Edwards will serve as a Class III director until the 2017 annual stockholder's meeting. The Company also announced that effective as of the same date, Ira Klein, MD, MBA, FACP resigned from the Company's Board of Directors.
Histogenics Corporation Announces Appointment of Stephen Kennedy to Chief Technology Officer
WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the promotion of Stephen Kennedy to Chief Technology Officer, effective immediately. Mr. Kennedy brings more than 30 years of executive product development, manufacturing, technology assessment and commercialization experience at leading biotechnology companies and esteemed academic institutions, including Genzyme, MIT, and Genencor. He has substantial experience taking early-stage technologies through development, approval and commercial launch using a variety of U.S. and global regulatory pathways, including biologics, drugs and medical devices, and will oversee all manufacturing, research & development, technology assessment, intellectual property and collaboration activities with our advisory board and collaboration partners.
Reed's Takes the Reins With the Moscow Mule Leading the Charge
LOS ANGELES, July 30, 2015 (GLOBE NEWSWIRE) -- Reed's, Inc. (NYSE MKT:REED), maker of the top-selling craft sodas in natural food stores nationwide, announced today that it is featured in the July issue of Bar Business Magazine, the premier publication, in print and online, for owners and operators in the nightlife and hospitality industry. Bar Business Magazine is the "How-to" resource for the nightlife industry, with nearly 100,000 qualified readers nationwide. Reed's new Stronger Ginger Brew is featured on the cover and is part of a six page spread which includes an interview with Chris Reed, Reed's Ginger Brew cocktail recipes and an ad showing the new joint partnership with Absolut Vodka.
Amyris Announces Closings of Conversion and Restructuring of Approximately $175 Million of Convertible Debt and $25 Million Private Placement
EMERYVILLE, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the closings of both its previously announced transactions for the conversion and restructuring of approximately $175 million of outstanding convertible debt into Amyris common stock, and a private placement of its common stock for aggregate proceeds of approximately $25 million. The company noted that details of these transactions are included in a related Form 8-K, which the company filed today in conjunction with this news release with the Securities and Exchange Commission (SEC).